Search

Ugur Banu Eskiocak

from Carlsbad, CA
Age ~41
Get Report
Also known as:
Ugur C Eskiocak, Eskiocak Ugur
Related to:
Banu Eskiocak, 41
Connected to:
Lesley D Esklund, 93David M Eskoff, 63Nancy A Eskola, 84Jack M Eskow, 114Rose EskowPaul D Eskra, 40Ross C Eskra, 36Bettie M Eskridge, 75Bonita Eskridge, 62Camille A Eskridge, 35

Ugur Eskiocak Phones & Addresses

  • Carlsbad, CA
  • Somerville, MA
  • Rancho Santa Fe, CA
  • Cambridge, MA
  • 6482 Bordeaux Ave, Dallas, TX 75209
  • Irving, TX

Publications

Us Patents

Treatments For Melanoma

View page
US Patent:
20140080772, Mar 20, 2014
Filed:
Sep 5, 2013
Appl. No.:
14/019258
Inventors:
Elena PISKOUNOVA - Dallas TX, US
Ugur ESKIOCAK - Dallas TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
A61K 31/7048
A61N 5/10
A61K 31/585
A61K 31/404
A61K 31/506
US Classification:
514 26, 514414, 514275, 514171, 600 1
Abstract:
The present invention relates to mono- and combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include RO 31-8220, bafetinib, and cardiac glycosides.

Combination Treatments For Melanoma

View page
US Patent:
20140066392, Mar 6, 2014
Filed:
Sep 5, 2013
Appl. No.:
14/019327
Inventors:
Elena PISKOUNOVA - Dallas TX, US
Ugur ESKIOCAK - Dallas TX, US
Assignee:
The Board of Regents of the University of Texas System - Austin TX
International Classification:
A61K 31/585
A61K 31/437
A61K 31/506
US Classification:
514 26, 514275, 514300
Abstract:
The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.

Combination Of Masked Ctla4 And Pd1/Pdl1 Antibodies For Treating Cancer

View page
US Patent:
20220340662, Oct 27, 2022
Filed:
Mar 1, 2022
Appl. No.:
17/684232
Inventors:
- Waltham MA, US
Ugur Eskiocak - Waltham MA, US
International Classification:
C07K 16/28
A61P 35/00
Abstract:
The invention provides activatable masked anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) in combination with PD-1 signaling agents inhibitors or PD-Li inhibitors) for use in treating cancer, as well as compositions and kits comprising the activatable masked anti-CTLA4 binding proteins and PD-1 signaling agents.

Combination Of Ctla4 And Pd1/Pdl1 Antibodies For Treating Cancer

View page
US Patent:
20220306743, Sep 29, 2022
Filed:
Mar 1, 2022
Appl. No.:
17/684211
Inventors:
- Waltham MA, US
Ugur Eskiocak - Waltham MA, US
International Classification:
C07K 16/28
A61P 35/00
A61K 47/68
Abstract:
The invention provides anti-CTLA4 binding proteins (e.g., antibodies, bispecific antibodies, and chimeric receptors) and their use in combination with PD-1 signaling agents (e.g., PD-1 inhibitors or PD-L1 inhibitors) for treating and preventing cancer, as well as compositions and kits comprising the anti-CTLA4 binding proteins and PD-1 signaling agents.

Tumor-Specific Cleavable Linkers

View page
US Patent:
20230072822, Mar 9, 2023
Filed:
Nov 24, 2021
Appl. No.:
17/535451
Inventors:
- Waltham MA, US
Ugur ESKIOCAK - Somerville MA, US
Huawei QIU - Westborough MA, US
Parker JOHNSON - Allston MA, US
Kurt Allen JENKINS - Weymouth MA, US
Dheeraj Singh TOMAR - Dorchester MA, US
Rebekah Kay O'DONNELL - Brookline MA, US
International Classification:
A61K 47/65
A61K 38/20
A61K 47/64
A61P 35/00
Abstract:
The present disclosure provides tumor-specific cleavable linkers and their use in drugs and prodrugs for delivering therapeutics to a tumor cell environment. The present disclosure also provides cleavage products of said drugs and prodrugs, and methods related to the use of the same.

Multispecific Binding Constructs Against Checkpoint Molecules And Uses Thereof

View page
US Patent:
20210284736, Sep 16, 2021
Filed:
May 20, 2021
Appl. No.:
17/325268
Inventors:
- Brighton MA, US
Rachel Rennard - Stoneham MA, US
Amanda Frank Oliphant - Boston MA, US
Cheuk Lun Leung - Quincy MA, US
Benjamin Jacob Wolf - Seattle WA, US
Ugur Eskiocak - Somerville MA, US
Pearl Bakhru - Ashland MA, US
Diana I. Albu - Windham NH, US
International Classification:
C07K 16/28
A61P 35/00
Abstract:
The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

Agonist Antibodies That Bind Human Cd137 And Uses Thereof

View page
US Patent:
20200306374, Oct 1, 2020
Filed:
Jun 8, 2020
Appl. No.:
16/895239
Inventors:
- Cambridge MA, US
Paul Widboom - Lebanon NH, US
Michael March Schmidt - Wellesley MA, US
Jason M. Lajoie - Brighton MA, US
Cheuk Lun Leung - Quincy MA, US
Ugur Eskiocak - Somerville MA, US
International Classification:
A61K 39/395
C07K 16/28
A61P 35/00
A61K 39/00
A61K 35/17
C12N 15/79
Abstract:
The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Cd137 Antibodies And Tumor Antigen-Targeting Antibodies And Uses Thereof

View page
US Patent:
20200308293, Oct 1, 2020
Filed:
Nov 20, 2018
Appl. No.:
16/765585
Inventors:
- Cambridge MA, US
Ugur Eskiocak - Somerville MA, US
International Classification:
C07K 16/28
A61P 35/00
C07K 16/32
C07K 16/40
Abstract:
The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.
Control profile
Ugur Banu Eskiocak from Carlsbad, CA, age ~41 Get Report